Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1614059

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1614059

Duchenne Muscular Dystrophy Drugs Market by Drug Type (Casimersen, Deflazacort, Delandistrogene Moxeparvovec), Administration Method (Oral, Parental), End-Use - Global Forecast 2025-2030

PUBLISHED:
PAGES: 197 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Duchenne Muscular Dystrophy Drugs Market was valued at USD 1.57 billion in 2023, expected to reach USD 1.70 billion in 2024, and is projected to grow at a CAGR of 8.61%, to USD 2.80 billion by 2030.

The Duchenne Muscular Dystrophy (DMD) Drugs market focuses on pharmaceuticals designed to treat symptoms or slow the progression of DMD, a rare genetic disorder characterized by progressive muscle degeneration and weakness. The need for such drugs is underscored by the absence of a definitive cure, thus making treatment for quality of life improvement and life extension vital. Applications of these drugs predominantly involve disease symptom management and muscle strength preservation, tailored to pediatric use due to the early onset of the disorder. Key end-users include hospitals, specialty clinics, and research institutions. Market growth is primarily driven by increasing awareness, advancements in genetic research, and regulatory incentives fostering orphan drug development. Gene therapy, exon-skipping drugs, and corticosteroids currently hold significant market potential. An opportunity exists in targeting untapped markets and enhancing personalized medicine approaches through genetic profiling technologies. However, the market encounters limitations such as high drug development costs, regulatory challenges, and the intricate nature of DMD genetics impacting treatment standardization. Additionally, a limited patient population imposes constraints on widespread commercial viability. Innovation areas include novel gene-editing techniques like CRISPR, development of next-generation exon-skipping drugs, and leveraging AI for accelerated drug discovery processes. The market remains dynamic, with pharmaceutical firms increasingly engaging in strategic partnerships to enhance research and commercialization capabilities. Nevertheless, adapting to regulatory updates and addressing the ethical concerns around genetic treatments remain pressing challenges. The landscape continues to evolve, promoting robust research and development ecosystems crucial for fostering breakthroughs. To leverage existing opportunities, firms are encouraged to prioritize collaborations with research communities, engage in cross-industry partnerships, and advocate for flexible regulatory frameworks to expedite the drug approval processes. Such measures can facilitate a competitive edge while ensuring sustainable market expansion in the DMD drug domain.

KEY MARKET STATISTICS
Base Year [2023] USD 1.57 billion
Estimated Year [2024] USD 1.70 billion
Forecast Year [2030] USD 2.80 billion
CAGR (%) 8.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Duchenne Muscular Dystrophy Drugs Market

The Duchenne Muscular Dystrophy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
    • Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
  • Market Restraints
    • High costs of DMD drug therapies
  • Market Opportunities
    • Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
    • Development of personalized medicine approaches tailored to individual genetic profiles
  • Market Challenges
    • Limited awareness and side affects associated with DMD drugs

Porter's Five Forces: A Strategic Tool for Navigating the Duchenne Muscular Dystrophy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Duchenne Muscular Dystrophy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Duchenne Muscular Dystrophy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Duchenne Muscular Dystrophy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Duchenne Muscular Dystrophy Drugs Market

A detailed market share analysis in the Duchenne Muscular Dystrophy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Duchenne Muscular Dystrophy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Duchenne Muscular Dystrophy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Duchenne Muscular Dystrophy Drugs Market

A strategic analysis of the Duchenne Muscular Dystrophy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Casimersen, Deflazacort, Delandistrogene Moxeparvovec, Eteplirsen, Golodirsen, and Viltolarsen.
  • Based on Administration Method, market is studied across Oral and Parental.
  • Based on End-Use, market is studied across Ambulatory Centres, Homecare Settings, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-5E3B35529469

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
      • 5.1.1.2. Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of DMD drug therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
      • 5.1.3.2. Development of personalized medicine approaches tailored to individual genetic profiles
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and side affects associated with DMD drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
    • 5.2.2. End-Use: Increasing adoption of DMD drugs in ambulatory centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Casimersen
  • 6.3. Deflazacort
  • 6.4. Delandistrogene Moxeparvovec
  • 6.5. Eteplirsen
  • 6.6. Golodirsen
  • 6.7. Viltolarsen

7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Duchenne Muscular Dystrophy Drugs Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Centres
  • 8.3. Homecare Settings
  • 8.4. Hospitals & Clinics

9. Americas Duchenne Muscular Dystrophy Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Agamree Receives FDA Approval as First "Dissociative Steroidal Anti-Inflammatory" to Treat Duchenne Muscular Dystrophy
    • 12.3.2. FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy
    • 12.3.3. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anuh Pharma Limited
  • 2. Arlak Biotech Pvt.Ltd.
  • 3. Aurigene Pharmaceutical Services Ltd.
  • 4. Bayer Pharmaceutical
  • 5. Cipla Inc.
  • 6. Enomark
  • 7. Glasier Wellness, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. Johnson & Johnson Services, Inc.
  • 10. Leo Pharma
  • 11. Lifecare Neuro Products Limited
  • 12. Mankind Pharma Ltd.
  • 13. Merck & Co., Inc.,
  • 14. MODASA Pharmaceuticals Pvt. Ltd.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. QndQ Derma
  • 18. RayBiotech, Inc.
  • 19. Ronyd Healthcare Pvt Ltd.
  • 20. Sarepta Therapeutics, Inc.
  • 21. Sumitomo Corporation
  • 22. Texas Pharmaceuticals Pvt. Ltd.
  • 23. Wallace Pharmaceuticals Pvt Ltd.
  • 24. Wellona Pharma
  • 25. Zuventus Healthcare Ltd.
Product Code: MRR-5E3B35529469

LIST OF FIGURES

  • FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!